Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma, Large B-Cell, Diffuse × orelabrutinib × Clear all

Phase

Status

Sponsor Class

OTHER 6 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Hematologic Neoplasms 1

Interventions

Rituximab 84 Cyclophosphamide 46 Prednisone 29 Doxorubicin 29 Vincristine 28 Gemcitabine 25 Lenalidomide 23 Oxaliplatin 20 Bendamustine Hydrochloride 16 ibrutinib 14 fludarabine 14 tisagenlecleucel 12 tafasitamab 11 venetoclax 10 polatuzumab vedotin 10 obinutuzumab 10 loncastuximab tesirine 9 Injections 8 Etoposide 8 zanubrutinib 7 pembrolizumab 7 Prednisolone 7 Ifosfamide 7 Carboplatin 7 tazemetostat 6 axicabtagene ciloleucel 6 selinexor 5 parsaclisib 5 glofitamab 5 R-CHOP protocol 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05234684 2024-02-07

BELIEVE-01

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 3 Unknown

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡